Weekly HIV Regimen Meets Phase 3 Goal
The investigational combination pairs islatravir and lenacapavir in a once-weekly single-tablet regimen.
By
Kathryn Wighton
June 10, 2026
Clinical Scorecard: Weekly HIV Regimen Meets Phase 3 Goal
At a Glance
Category Detail
Condition Key Mechanisms Islatravir inhibits HIV-1 replication through multiple mechanisms; Lenacapavir acts at multiple stages of the HIV life cycle. Target Population Care Setting
Key Highlights
Phase 3 ISLEND-1 and ISLEND-2 trials met primary efficacy endpoints at week 48. Investigational regimen of islatravir and lenacapavir was statistically noninferior to standard daily therapy. Safety profile of the investigational regimen was comparable to comparator regimens. No new safety concerns were identified in both studies. Guideline-Based Recommendations
Diagnosis
Management
Switching to once-weekly islatravir/lenacapavir is investigational and not yet approved. Monitoring & Follow-up
Risks
Patient & Prescribing Data
Patients with virologically suppressed HIV
Combination of islatravir and lenacapavir is investigational and shows promise for once-weekly dosing.
Clinical Best Practices
Related Resources & Content
